Cancer News and Research

Latest Cancer News and Research

CAR-T cell therapy remains viable for patients in lymphoma remission, study finds

A study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins.

11 Dec 2023

New drug combo shows promise in targeting RAS-mutant multiple myeloma

The combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows.

11 Dec 2023

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes (MDS) and other myeloid neoplasms.

11 Dec 2023

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.

11 Dec 2023

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.

11 Dec 2023

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

11 Dec 2023

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

11 Dec 2023

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

11 Dec 2023

New organoid model could revolutionize neuroendocrine tumor research

The Organoid Group (Hubrecht Institute) and the Rare Cancers Genomics Team (IARC/WHO) found a way to grow samples of different types of neuroendocrine tumors (NETs) in the lab.

11 Dec 2023

AI chatbot could be a useful clinical decision support tools for physicians

Physician-investigators at Beth Israel Deaconess Medical Center (BIDMC) compared a chatbot's probabilistic reasoning to that of human clinicians.

11 Dec 2023

New map offers valuable insights into the underlying mechanisms of neurodevelopmental disorders and cancer

Scientists have created the first extensive map showing how all possible genetic changes can affect health in the gene DDX3X, leading to valuable insights into the underlying mechanisms of neurodevelopmental disorders and cancer.

11 Dec 2023

Breakthrough in pancreatic cancer treatment: Inhibiting specific enzymes slows tumor progression

Study demonstrates that inhibiting stromal class I histone deacetylases (HDACs) can effectively slow down pancreatic cancer progression, shedding light on a new therapeutic approach targeting the tumor microenvironment.

10 Dec 2023

Understanding why healthy cells help cancer cells to evade treatment

Chemotherapy becomes less effective because healthy cells push cancer cells to grow more slowly, according to two studies from researchers at UCL and Yale.

9 Dec 2023

Women over 50 can safely reduce mammogram frequency after breast cancer surgery

Women 50 or older who de-escalated to less-frequent mammography three years after curative surgery for early-stage breast cancer had similar outcomes to women who received annual mammography, according to results from the Mammo-50 trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.

8 Dec 2023

Low-risk DCIS patients may safely skip radiotherapy after surgery, study finds

Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS who received adjuvant radiotherapy, according to results from the E4112 clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.

8 Dec 2023

MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers

The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia (AML) and other hematologic cancers.

8 Dec 2023

Study identifies targetable fusion RNAs in breast cancer

Comprehensive profiling of fusion RNAs present in a large cohort of metastatic breast tumors revealed unique fusion mutations that may be therapeutically targetable, according to results presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.

8 Dec 2023

Cancer News and Research

Latest Cancer News and Research

CAR-T cell therapy remains viable for patients in lymphoma remission, study finds

New drug combo shows promise in targeting RAS-mutant multiple myeloma

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

New organoid model could revolutionize neuroendocrine tumor research

AI chatbot could be a useful clinical decision support tools for physicians

New map offers valuable insights into the underlying mechanisms of neurodevelopmental disorders and cancer

Breakthrough in pancreatic cancer treatment: Inhibiting specific enzymes slows tumor progression

Understanding why healthy cells help cancer cells to evade treatment

Women over 50 can safely reduce mammogram frequency after breast cancer surgery

Low-risk DCIS patients may safely skip radiotherapy after surgery, study finds

MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers

Study identifies targetable fusion RNAs in breast cancer

Women undergoing chemotherapy may not benefit from common fertility protection drug

Small molecule drug shows promise as potential new treatment for multiple sclerosis

Exploring the role of liquid biopsies in early-stage prostate cancer

Understanding the DNA Damage Response in Innate Immunity eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in